Performance measures in Friedreich ataxia: Potential utility as clinical outcome tools

Movement Disorders

Volumn 20, Issue 7, 2005, Pages 777-782

  Lynch, David R ^a,b   Farmer, Jennifer M ^a   Wilson, Robert L ^a   Balcer, Laura J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Antioxidant; Cardiomyopathy; Composite measure; Diabetes; Mitochondrial disease

Indexed keywords

ADOLESCENT; ADULT; AGE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE COURSE; DISEASE DURATION; FOOT; FRIEDREICH ATAXIA; FUNCTION TEST; HUMAN; LINEAR REGRESSION ANALYSIS; MOTOR PERFORMANCE; NEUROLOGIC DISEASE; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; RATING SCALE; SCHOOL CHILD; SCORING SYSTEM; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS; WALKING;

ADULT; CROSS-SECTIONAL STUDIES; DISABILITY EVALUATION; FEMALE; FRIEDREICH ATAXIA; HUMANS; LOGISTIC MODELS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOMOTOR PERFORMANCE; REPRODUCIBILITY OF RESULTS; SICKNESS IMPACT PROFILE; TRINUCLEOTIDE REPEATS; VISUAL ACUITY; WALKING;

EID: 24144449944     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20449     Document Type: Article

References (18)

1. Lynch DR, Farmer JM, Balcer LJ, Wilson RB. Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. Arch Neurol 2002;59:743-747.
2. Cossee M, Durr A, Schmitt M, et al. Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 1999;45:200-206.
3. Lodi R, Hart PE, Rajagopalan B, et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann Neurol 2001;49:590-596.
4. Mariotti C, Solari A, Torta D, Marano L, Fiorentini C, DiDonato S. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 2003;60:1676-1679.
5. Cohen JA, Fischer JS, Bolibrush DM, et al. Intrarater and interrater reliability of the MS functional composite outcome measure. Neurology 2000;54:802-806.
6. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122:871-882.
7. Lynch DR, Farmer JM, Rochestie D, Balcer LJ. Contrast letter acuity as a measure of visual dysfunction in patients with Friedreich ataxia. J Neuroophthalmol 2002;22:270-274.
8. Trouillas P, Takayanagi T, Hallett M, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 1997;145:205-211.
9. Rudick RA, Cutter G, Reingold S. The multiple sclerosis functional composite: a new clinical outcome measure for multiple sclerosis trials. Mult Scler 2002;8:359-365.
10. McCormack ML, Guttmann RP, Schumann M, et al. Novel frataxin point mutations in 2 patients with Friedreich ataxia and unusual clinical features. J Neurol Neurosurg Psychiatry 2000;68: 661-664.
11. Bidichandani SI, Garcia CA, Patel PI, Dimachkie MM. Very late-onset Friedreich ataxia despite large GAA triplet repeat expansions. Arch Neurol 2000;57:246-251.
12. McCabe DJ, Wood NW, Ryan F, et al. Intrafamilial phenotypic variability in Friedreich ataxia associated with a G130V mutation in the FRDA gene. Arch Neurol 2002;59:296-300.
13. Webb S, Doudney K, Pook M, Chamberlain S, Hutchinson M. A family with pseudodominant Friedreich's ataxia showing marked variation of phenotype between affected siblings. J Neurol Neurosurg Psychiatry 1999;67:217-219.
14. Schulte T, Mattern R, Berger K, Szymanski S, Klotz P, Kraus PH, et al. Double-blind crossover trial of tiimethoprim-sulfamethoxazole in spinocerebellar ataxia type 3/Machado-Joseph disease. Arch Neurol 2001;58:1451-1457.
15. Furman JM, Perlman S, Baloh RW. Eye movements in Friedreich's ataxia. Arch Neurol 1983;40:343-346.
16. Balcer LJ, Baier ML, Cohen JA, et al. Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology 2003;61:1367-1373.
17. Subramony SH, May W, Lynch DR, et al. Inter-rater reliability of a neurological rating scale for Friedreich ataxia. Neurology (in press).
18. Balcer LJ, Baier ML, Pelak VS, et al. New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis. Mult Scler 2000;6:163-171.